Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Employees - 21,
CEO - Mr. Fady Boctor M.B.A.,
Sector - Healthcare,
Country - US,
Market Cap - 3.66M
Altman ZScore(max is 10): -7.55, Piotroski Score(max is 10): 3, Working Capital: $-1837624, Total Assets: $20693630, Retained Earnings: $-103934931, EBIT: -4207928, Total Liabilities: $17576521, Revenue: $4022393
- Current Price $0.07 - Analyst Target Price $1.00| Ticker | PTPI |
| Index | - |
| Curent Price | 0.07 |
| Change | -4.86% |
| Market Cap | 3.66M |
| Average Volume | 36.16M |
| Income | -26.80M |
| Sales | 5.11M |
| Book Value/Share | -0.71 |
| Cash/Share | 0.07 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 18 |
| Moving Avg 20days | -18.84% |
| Moving Avg 50days | -56.59% |
| Moving Avg 200days | -77.65% |
| Shares Outstanding | 29.93M |
| Earnings Date | - |
| Inst. Ownership | 3.25% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 0.72 |
| Price/Book | - |
| Price/Cash | 0.99 |
| Price/FCF | - |
| Quick Ratio | 0.33 |
| Current Ratio | 0.40 |
| Debt/Equity | - |
| Return on Assets | - |
| Return on Equity | - |
| Return on Investment | - |
| Gross Margin | 20.89% |
| Ops Margin | -201.41% |
| Profit Margin | -524.20% |
| RSI | 40.72 |
| BETA(β) | 2.09 |
| From 52week Low | 26.38% |
| From 52week High | -93.35% |
| EPS | -3.62 |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | 55.46% |
| Sales past 5 Year | -19.05% |
| EPS Y/Y | 41.73% |
| Sales Y/Y | - |
| EPS Q/Q | 55.57% |
| Sales Q/Q | -56.68% |
| Sales Surprise | 0.01% |
| EPS Surprise | 0.00% |
| ATR(14) | 0.03 |
| Perf Week | -38.29% |
| Perf Month | -23.89% |
| Perf Quarter | -82.61% |
| Perf Year | -93.60% |
| Perf YTD | -82.61% |
| Target Price | 1.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer